Gynecological

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(CCTG) OVC.2 / NRG-GY005A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)Hirte, Dr HalOpen to recruitmentNCT02502266
(Clovis) CO-338-087 / GOG-3020 / ENGOT-ov45/NCRI/ATHENAA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyElit, Dr LaurieOpen to recruitmentNCT03522246
(ImmunoGen) IMGN853-0402A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube CancerHirte, Dr HalOpen to recruitmentNCT02606305
(Merck) MK-3475-826 / KEYNOTE 826A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Locally Advanced or Metastatic Cervical Cancer (KEYNOTE-826)Hirte, Dr HalOpen to recruitmentNCT03635567
(Tesaro) 3000-03-005 / ENGOT-OV44 / FIRSTA Patient Centric Randomized Phase 3 Comparison of Standard of Care Platinum Based Therapy to the Same Plus TSR-042 As First Line Treatment of Patients with Stage III or IV Non-Mucinous Ovarian Cancer.Hirte, Dr HalOpen to recruitmentNCT03602859
(UHN) BioDIVABiomarker Discovery Project in High Grade Serous Ovarian CancerElit, Dr LaurieOpen to recruitmentNCT03419689
Download PDF